Canakinumab injection
Products billed under this code include Ilaris.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Ilaris.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ilaris | Novartis Pharmaceuticals Corporation | 00078-0734-61 | 150 | $23,542.95 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $156.953 | +$0.412 | 1 MG | Canakinumab injection | v1, posted September 17, 2026 |
| 3Q26 | $156.541 | +$6.967 | 1 MG | Canakinumab injection | v1, posted September 15, 2026 |
| 2Q26 | $149.574 | +$1.833 | 1 MG | Canakinumab injection | v1, posted September 15, 2026 |
| 1Q26 | $147.741 | +$6.137 | 1 MG | Canakinumab injection | v1, posted September 15, 2026 |
| 4Q25 | $141.604 | +$0.608 | 1 MG | Canakinumab injection | v1, posted September 8, 2026 |
| 3Q25 | $140.996 | +$4.439 | 1 MG | Canakinumab injection | v1, posted March 10, 2026 |
| 2Q25 | $136.557 | +$0.679 | 1 MG | Canakinumab injection | v1, posted March 10, 2026 |
| 1Q25 | $135.878 | +$8.068 | 1 MG | Canakinumab injection | v1, posted December 19, 2025 |
| 4Q24 | $127.81 | +$1.265 | 1 MG | Canakinumab injection | v1, posted June 11, 2025 |
| 3Q24 | $126.545 | +$2.061 | 1 MG | Canakinumab injection | v1, posted June 11, 2025 |
| 2Q24 | $124.484 | +$0.158 | 1 MG | Canakinumab injection | v1, posted March 11, 2025 |
| 1Q24 | $124.326 | +$2.271 | 1 MG | Canakinumab injection | v1, posted December 19, 2024 |
| 4Q23 | $122.055 | +$0.542 | 1 MG | Canakinumab injection | v1, posted October 10, 2024 |
| 3Q23 | $121.513 | +$1.692 | 1 MG | Canakinumab injection | v1, posted June 5, 2024 |
| 2Q23 | $119.821 | +$0.263 | 1 MG | Canakinumab injection | v1, posted February 23, 2024 |
| 1Q23 | $119.558 | +$0.831 | 1 MG | Canakinumab injection | v1, posted December 6, 2023 |
| 4Q22 | $118.727 | +$0.118 | 1 MG | Canakinumab injection | v1, posted June 22, 2023 |
| 3Q22 | $118.609 | +$1.667 | 1 MG | Canakinumab injection | v1, posted June 9, 2023 |
| 2Q22 | $116.942 | +$1.053 | 1 MG | Canakinumab injection | v1, posted December 14, 2022 |
| 1Q22 | $115.889 | +$0.283 | 1 MG | Canakinumab injection | v1, posted June 8, 2022 |
| 4Q21 | $115.606 | +$0.183 | 1 MG | Canakinumab injection | v1, posted June 2, 2022 |
| 3Q21 | $115.423 | +$2.102 | 1 MG | Canakinumab injection | v1, posted June 2, 2022 |
| 2Q21 | $113.321 | +$0.063 | 1 MG | Canakinumab injection | v1, posted March 1, 2022 |
| 1Q21 | $113.258 | – | 1 MG | Canakinumab injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.